First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model

Alzheimer's Research and Therapy

Volumn 6, Issue 4, 2014, Pages

  Kontsekova, Eva ^a   Zilka, Norbert ^a   Kovacech, Branislav ^a,b   Novak, Petr ^a   Novak, Michal ^a  

^a Axon Neuroscience GmbH   (Slovakia)

^b Institute of Neuroimmunology   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

AADVAC1 PEPTIDE VACCINE; ALUMINUM HYDROXIDE; ALZHEIMER DISEASE VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; OLIGOMER; PEPTIDE VACCINE; PLACEBO; TAU PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BEAGLE; BRAIN TISSUE; CHRONIC TOXICITY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL RABBIT; GOOD LABORATORY PRACTICE; GRANULOMATOUS INFLAMMATION; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE FIBER DEGENERATION; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; PAIRED HELICAL FILAMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RAT; SENSORIMOTOR FUNCTION; SINGLE DRUG DOSE; TAUOPATHY; TRACTION TEST;

EID: 84908290432     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt278     Document Type: Article

References (43)

1. Neuropathological stageing of Alzheimer-related changes. Braak H, Braak E, Acta Neuropathol 1991 82 239 259
2. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW, Lancet Neurol 2011 10 785 796
3. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, et al. J Neuropathol Exp Neurol 2012 71 362 381
4. The global prevalence of dementia: a systematic review and metaanalysis. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP, Alzheimers Dement 2013 9 63 75 e2
5. Treatment of Alzheimer's disease across the spectrum of severity. Shah S, Reichman WE, Clin Interv Aging 2006 1 131 142
6. Immunotherapy for Alzheimer's disease: hoops and hurdles. Lemere CA, Mol Neurodegener 2013 8 36
7. Alzheimer's disease: clinical trials and drug development. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M, Lancet Neurol 2010 9 702 716
8. Amyloid-β immunization in Alzheimer's disease transgenic mouse models and wildtype mice. Lemere CA, Spooner ET, Leverone JF, Mori C, Iglesias M, Bloom JK, Seabrook TJ, Neurochem Res 2003 28 1017 1027
9. Tau aggregates as immunotherapeutic targets. Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R, Front Biosci (Schol Ed) 2013 5 426 438
10. Immunotherapy for tauopathies. Gu J, Sigurdsson EM, J Mol Neurosci 2011 45 690 695
11. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A, Immunotherapy 2012 4 213 238
12. Therapeutic strategies for tau mediated neurodegeneration. Yoshiyama Y, Lee VM, Trojanowski JQ, J Neurol Neurosurg Psychiatry 2013 84 784 795
13. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM, J Neurosci 2007 27 9115 9129
14. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. Bi M, Ittner A, Ke YD, Götz J, Ittner LM, PLoS One 2011 6 26860
15. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H, Exp Neurol 2010 224 472 485
16. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. Boutajangout A, Quartermain D, Sigurdsson EM, J Neurosci 2010 30 16559 16566
17. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M, J Biol Chem 2011 286 34457 34467
18. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, López-Deber MP, Reis P, Hickman DT, Adolfsson O, Chuard N, Ndao DM, Borghgraef P, Devijver H, Van Leuven F, Pfeifer A, Muhs A, PLoS One 2013 8 72301
19. Targeting phospho-Ser422 by active Tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L, Curr Alzheimer Res 2012 9 397 405
20. T-cell epitope-dependent immune response in inbred (C57BL/6 J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice. Richter M, Hoffmann R, Singer D, J Pept Sci 2013 19 441 451
21. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, Reynolds CH, Ward MA, Anderton BH, J Biol Chem 2007 282 23645 23654
22. Proline-directed and non-proline-directed phosphorylation of PHF-tau. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, Ihara Y, J Biol Chem 1995 270 823 829
23. First transgenic rat model developing progressive cortical neurofibrillary tangles. Filipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M, Neurobiol Aging 2012 33 1448 1456
24. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M, Eur J Neurosci 2008 28 239 246
25. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G, Kontsekova E, Novak M, FEBS Lett 2006 580 3582 3588
26. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Nakamura K, Greenwood A, Binder L, Bigio EH, Denial S, Nicholson L, Zhou XZ, Lu KP, Cell 2012 149 232 244
27. Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies. Hanes J, Zilka N, Bartkova M, Caletkova M, Dobrota D, Novak M, J Neurochem 2009 108 1167 1176
28. The self-perpetuating tau truncation circle. Zilka N, Kovacech B, Barath P, Kontsekova E, Novák M, Biochem Soc Trans 2012 40 681 686
29. Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer's disease cellular model. Zilkova M, Zilka N, Kovac A, Kovacech B, Skrabana R, Skrabanova M, Novak M, J Alzheimers Dis 2011 23 161 169
30. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M, Alzheimers Res Ther 2014 6 45 doi:10.1186/alzrt277
31. High-yield purification of fetal tau preserving its structure and phosphorylation pattern. Ivanovova N, Handzusova M, Hanes J, Kontsekova E, Novak M, J Immunol Methods 2008 339 17 22
32. NeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model of tauopathy. Korenova M, Zilka N, Stozicka Z, Bugos O, Vanicky I, Novak M, J Neurosci Methods 2009 177 108 114
33. CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy. Zilka N, Korenova M, Kovacech B, Iqbal K, Novak M, Acta Neuropathol 2010 119 679 687
34. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, Bugiani O, Del-Tredici K, Ferrer I, Gelpi E, Giaccone G, Graeber MB, Ince P, Kamphorst W, King A, Korkolopoulou P, Kovács GG, Larionov S, Meyronet D, Monoranu C, Parchi P, Patsouris E, Roggendorf W, Seilhean D, Tagliavini F, Stadelmann C, Streichenberger N, Thal DR, Wharton SB, Kretzschmar H, Brain Pathol 2008 18 484 496
35. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR, Brain Res Brain Res Rev 2000 33 95 130
36. Tau-targeted treatment strategies in Alzheimer's disease. Götz J, Ittner A, Ittner LM, Br J Pharmacol 2012 165 1246 1259
37. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. Zilka N, Kontsekova E, Novak M, J Alzheimers Dis 2008 15 169 179
38. Immunotherapy as treatment for Alzheimer's disease. Hawkes CA, McLaurin J, Expert Rev Neurother 2007 7 1535 1548
39. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Robinson SR, Bishop GM, Lee HG, Münch G, Neurobiol Aging 2004 25 609 615
40. Vaccine adjuvants: current challenges and future approaches. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B, J Pharm Sci 2009 98 1278 1316
41. The relationship between subcortical tau pathology and Alzheimer's disease. Attems J, Thal DR, Jellinger KA, Biochem Soc Trans 2012 40 711 715
42. Motor signs predict poor outcomes in Alzheimer disease. Scarmeas N, Albert M, Brandt J, Blacker D, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Wegesin D, Marder K, Bell K, Honig L, Stern Y, Neurology 2005 64 1696 1703
43. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Hrnkova M, Zilka N, Minichova Z, Koson P, Novak M, Brain Res 2007 1130 206 213